Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 55.56 percent increase over losses of $(0.18) per share from the same period last year. The company reported quarterly sales of $15.961 million which beat the analyst consensus estimate of $15.948 million by 0.08 percent. This is a 21.48 percent increase over sales of $13.139 million the same period last year.